Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor. [PDF]
Gou X +7 more
europepmc +1 more source
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. [PDF]
Kheloussi S +4 more
europepmc +1 more source
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen +10 more
wiley +1 more source
Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report. [PDF]
Yu M, Tian S, Meng F.
europepmc +1 more source
ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim +5 more
wiley +1 more source
Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance. [PDF]
Prasad S +6 more
europepmc +1 more source
ABSTRACT Objective Soluble receptor for advanced glycation end‐products (sRAGE) and soluble Toll‐like receptor 4 (sTLR4) are circulating pattern recognition receptor isoforms implicated in inflammatory regulation in type 2 diabetes mellitus (T2DM). This study examined the effects of supervised aerobic exercise training (AET) on circulating sRAGE, sTLR4,
Ryan K. Perkins +9 more
wiley +1 more source
Comment on "Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial". [PDF]
Ayesha S, Parveen U, Irshad NUN.
europepmc +1 more source
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. [PDF]
Rhee SY +5 more
europepmc +1 more source
Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux +14 more
wiley +1 more source

